 Robert Brown
Concepts (676)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Amyotrophic Lateral Sclerosis | 76 | 2018 | 257 | 15.110 |
Why?
| | Superoxide Dismutase | 40 | 2018 | 178 | 7.110 |
Why?
| | Motor Neurons | 22 | 2016 | 124 | 3.060 |
Why?
| | Asthma | 9 | 2017 | 287 | 2.960 |
Why?
| | Lung | 11 | 2017 | 472 | 2.670 |
Why?
| | Mutation | 41 | 2018 | 1740 | 2.640 |
Why?
| | Genetic Predisposition to Disease | 24 | 2016 | 455 | 2.240 |
Why?
| | Bronchoconstriction | 6 | 2015 | 22 | 2.060 |
Why?
| | Methacholine Chloride | 6 | 2015 | 25 | 1.810 |
Why?
| | Motor Neuron Disease | 9 | 2015 | 24 | 1.730 |
Why?
| | Tomography, X-Ray Computed | 13 | 2017 | 857 | 1.690 |
Why?
| | Humans | 116 | 2018 | 34250 | 1.590 |
Why?
| | Airway Resistance | 6 | 2015 | 16 | 1.560 |
Why?
| | Inhalation | 4 | 2014 | 8 | 1.500 |
Why?
| | Muscle Proteins | 6 | 2010 | 98 | 1.470 |
Why?
| | Animals | 73 | 2018 | 14730 | 1.400 |
Why?
| | Disease Models, Animal | 16 | 2018 | 1192 | 1.330 |
Why?
| | Bronchial Provocation Tests | 4 | 2015 | 22 | 1.320 |
Why?
| | Membrane Proteins | 7 | 2010 | 658 | 1.310 |
Why?
| | Polymorphism, Single Nucleotide | 13 | 2013 | 322 | 1.300 |
Why?
| | Mice | 48 | 2018 | 7389 | 1.250 |
Why?
| | Muscle, Skeletal | 6 | 2014 | 474 | 1.240 |
Why?
| | Mice, Transgenic | 22 | 2018 | 946 | 1.220 |
Why?
| | Latex Hypersensitivity | 4 | 2010 | 5 | 1.200 |
Why?
| | Cytoskeletal Proteins | 3 | 2016 | 136 | 1.160 |
Why?
| | Promoter Regions, Genetic | 8 | 2012 | 579 | 1.110 |
Why?
| | RNA-Binding Protein FUS | 5 | 2015 | 24 | 1.100 |
Why?
| | Axons | 5 | 2016 | 117 | 1.040 |
Why?
| | Muscular Dystrophies | 4 | 2007 | 14 | 1.030 |
Why?
| | Bronchial Hyperreactivity | 2 | 2015 | 27 | 1.020 |
Why?
| | Female | 55 | 2017 | 18906 | 1.010 |
Why?
| | Male | 54 | 2017 | 17274 | 1.000 |
Why?
| | Forced Expiratory Volume | 5 | 2015 | 68 | 0.970 |
Why?
| | Bronchoconstrictor Agents | 4 | 2015 | 9 | 0.930 |
Why?
| | Middle Aged | 37 | 2017 | 9898 | 0.900 |
Why?
| | Frontotemporal Dementia | 4 | 2016 | 48 | 0.900 |
Why?
| | Adult | 32 | 2017 | 9715 | 0.870 |
Why?
| | DNA Repeat Expansion | 2 | 2015 | 14 | 0.840 |
Why?
| | Protein Disulfide-Isomerases | 2 | 2016 | 11 | 0.840 |
Why?
| | Armadillo Domain Proteins | 2 | 2016 | 14 | 0.830 |
Why?
| | Hereditary Sensory and Autonomic Neuropathies | 5 | 2015 | 5 | 0.830 |
Why?
| | NF-E2-Related Factor 2 | 2 | 2015 | 2 | 0.810 |
Why?
| | Neuromuscular Junction | 2 | 2009 | 77 | 0.770 |
Why?
| | Bronchi | 1 | 2017 | 68 | 0.750 |
Why?
| | Proteins | 4 | 2016 | 579 | 0.720 |
Why?
| | Isothiocyanates | 2 | 2015 | 9 | 0.710 |
Why?
| | Hypertension, Pulmonary | 1 | 2016 | 43 | 0.700 |
Why?
| | Neurons | 11 | 2015 | 620 | 0.700 |
Why?
| | Muscle, Smooth | 2 | 2014 | 94 | 0.690 |
Why?
| | Endogenous Retroviruses | 1 | 2015 | 2 | 0.690 |
Why?
| | Genotype | 10 | 2015 | 480 | 0.680 |
Why?
| | Respiratory System | 2 | 2008 | 28 | 0.680 |
Why?
| | Dipeptides | 1 | 2015 | 31 | 0.680 |
Why?
| | Genetic Variation | 6 | 2017 | 252 | 0.680 |
Why?
| | Spinal Cord | 10 | 2013 | 107 | 0.660 |
Why?
| | Lung Diseases | 1 | 2016 | 107 | 0.660 |
Why?
| | Phenotype | 8 | 2014 | 800 | 0.650 |
Why?
| | Brain Injuries | 1 | 2016 | 78 | 0.640 |
Why?
| | Recovery of Function | 1 | 2016 | 148 | 0.640 |
Why?
| | Genome-Wide Association Study | 7 | 2016 | 169 | 0.630 |
Why?
| | Haplotypes | 5 | 2009 | 104 | 0.630 |
Why?
| | Antioxidants | 1 | 2015 | 149 | 0.620 |
Why?
| | Sarcolemma | 2 | 2004 | 9 | 0.610 |
Why?
| | Activating Transcription Factor 3 | 1 | 2014 | 6 | 0.610 |
Why?
| | Bariatric Surgery | 1 | 2014 | 27 | 0.610 |
Why?
| | Respiration | 2 | 2005 | 67 | 0.600 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2013 | 148 | 0.590 |
Why?
| | Bronchodilator Agents | 3 | 2010 | 52 | 0.590 |
Why?
| | Capnography | 1 | 2013 | 10 | 0.570 |
Why?
| | Bulbar Palsy, Progressive | 1 | 2012 | 5 | 0.550 |
Why?
| | MicroRNAs | 3 | 2016 | 427 | 0.550 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2012 | 17 | 0.540 |
Why?
| | Polymorphism, Genetic | 8 | 2012 | 168 | 0.530 |
Why?
| | Weight Loss | 1 | 2014 | 200 | 0.530 |
Why?
| | Aryldialkylphosphatase | 2 | 2010 | 20 | 0.530 |
Why?
| | Aged | 22 | 2016 | 7665 | 0.520 |
Why?
| | Nerve Degeneration | 5 | 2015 | 49 | 0.520 |
Why?
| | Nerve Tissue Proteins | 6 | 2015 | 358 | 0.520 |
Why?
| | Carrier Proteins | 3 | 2012 | 617 | 0.520 |
Why?
| | Serine C-Palmitoyltransferase | 4 | 2011 | 5 | 0.510 |
Why?
| | Mutation, Missense | 4 | 2016 | 119 | 0.490 |
Why?
| | Annexins | 2 | 2017 | 6 | 0.490 |
Why?
| | Vanadium | 1 | 2010 | 2 | 0.490 |
Why?
| | Proteostasis Deficiencies | 1 | 2010 | 4 | 0.490 |
Why?
| | Cell Cycle Proteins | 2 | 2015 | 295 | 0.480 |
Why?
| | Manganese | 1 | 2010 | 19 | 0.480 |
Why?
| | Aluminum | 1 | 2010 | 13 | 0.480 |
Why?
| | Neuroprotective Agents | 3 | 2006 | 49 | 0.480 |
Why?
| | Age of Onset | 8 | 2012 | 131 | 0.480 |
Why?
| | Magnesium | 1 | 2010 | 45 | 0.480 |
Why?
| | Aging | 4 | 2015 | 522 | 0.480 |
Why?
| | Genetic Association Studies | 3 | 2015 | 72 | 0.480 |
Why?
| | Hair | 1 | 2010 | 40 | 0.470 |
Why?
| | Muscular Diseases | 1 | 2010 | 36 | 0.460 |
Why?
| | Drug Evaluation, Preclinical | 3 | 2006 | 62 | 0.450 |
Why?
| | Patients | 1 | 2010 | 63 | 0.450 |
Why?
| | Gene Expression | 5 | 2018 | 612 | 0.440 |
Why?
| | Dependovirus | 4 | 2018 | 324 | 0.440 |
Why?
| | Interleukin-13 | 2 | 2010 | 50 | 0.440 |
Why?
| | Interleukin-18 | 2 | 2010 | 59 | 0.440 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 3 | 2010 | 98 | 0.430 |
Why?
| | Genes, Dominant | 3 | 2005 | 55 | 0.430 |
Why?
| | DNA-Binding Proteins | 6 | 2015 | 1012 | 0.430 |
Why?
| | Cell Survival | 9 | 2014 | 452 | 0.430 |
Why?
| | Axonal Transport | 3 | 2015 | 21 | 0.420 |
Why?
| | Young Adult | 9 | 2015 | 2171 | 0.420 |
Why?
| | Transcription, Genetic | 2 | 2012 | 788 | 0.420 |
Why?
| | Obesity | 2 | 2014 | 869 | 0.410 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2015 | 287 | 0.410 |
Why?
| | Fibroblasts | 2 | 2014 | 287 | 0.410 |
Why?
| | Health Personnel | 1 | 2010 | 148 | 0.410 |
Why?
| | Sequence Deletion | 1 | 2008 | 99 | 0.410 |
Why?
| | Pluripotent Stem Cells | 1 | 2008 | 45 | 0.410 |
Why?
| | Golgi Apparatus | 1 | 2008 | 51 | 0.410 |
Why?
| | Tetanus Toxin | 4 | 2009 | 7 | 0.400 |
Why?
| | Cells, Cultured | 11 | 2015 | 1802 | 0.390 |
Why?
| | Neurotoxins | 3 | 2013 | 9 | 0.390 |
Why?
| | Vesicular Transport Proteins | 1 | 2008 | 90 | 0.380 |
Why?
| | Disease Progression | 7 | 2016 | 483 | 0.380 |
Why?
| | Mitochondria | 2 | 2010 | 202 | 0.370 |
Why?
| | DNA Mutational Analysis | 7 | 2013 | 149 | 0.370 |
Why?
| | Gene Expression Regulation | 6 | 2015 | 1219 | 0.370 |
Why?
| | Quadriceps Muscle | 1 | 2006 | 7 | 0.370 |
Why?
| | Immunohistochemistry | 9 | 2013 | 774 | 0.370 |
Why?
| | Muscle Hypotonia | 1 | 2006 | 9 | 0.370 |
Why?
| | Cell Differentiation | 3 | 2014 | 1044 | 0.370 |
Why?
| | Mutant Proteins | 4 | 2012 | 82 | 0.360 |
Why?
| | Laminin | 1 | 2006 | 79 | 0.360 |
Why?
| | Total Lung Capacity | 3 | 2017 | 9 | 0.360 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2006 | 53 | 0.360 |
Why?
| | Dogs | 6 | 2008 | 242 | 0.350 |
Why?
| | Peptide Fragments | 4 | 2009 | 293 | 0.350 |
Why?
| | Amino Acid Sequence | 10 | 2016 | 1497 | 0.350 |
Why?
| | Cell Death | 3 | 2013 | 208 | 0.340 |
Why?
| | Anterior Horn Cells | 2 | 2006 | 5 | 0.340 |
Why?
| | Guanine Nucleotide Exchange Factors | 3 | 2015 | 46 | 0.340 |
Why?
| | Anesthetics, Inhalation | 1 | 2005 | 21 | 0.340 |
Why?
| | Time Factors | 6 | 2015 | 2611 | 0.330 |
Why?
| | Apnea | 1 | 2005 | 27 | 0.330 |
Why?
| | Excitatory Amino Acid Transporter 2 | 1 | 2005 | 2 | 0.330 |
Why?
| | Anesthesia | 1 | 2005 | 42 | 0.330 |
Why?
| | Thermography | 1 | 2005 | 5 | 0.330 |
Why?
| | Case-Control Studies | 8 | 2014 | 660 | 0.330 |
Why?
| | Ceftriaxone | 1 | 2005 | 15 | 0.330 |
Why?
| | Bronchoscopy | 1 | 2005 | 39 | 0.320 |
Why?
| | Enzyme Inhibitors | 1 | 2006 | 279 | 0.320 |
Why?
| | Latex | 1 | 2004 | 5 | 0.320 |
Why?
| | Gloves, Surgical | 1 | 2004 | 3 | 0.320 |
Why?
| | Glial Cell Line-Derived Neurotrophic Factor | 3 | 2009 | 6 | 0.320 |
Why?
| | Allergens | 1 | 2004 | 24 | 0.310 |
Why?
| | Linkage Disequilibrium | 4 | 2012 | 34 | 0.310 |
Why?
| | Wallerian Degeneration | 2 | 2016 | 14 | 0.310 |
Why?
| | Neuroblastoma | 2 | 2006 | 69 | 0.310 |
Why?
| | Sequence Analysis, DNA | 5 | 2016 | 308 | 0.310 |
Why?
| | Gene Frequency | 4 | 2010 | 104 | 0.300 |
Why?
| | Brain | 6 | 2015 | 850 | 0.300 |
Why?
| | Cyclosporine | 1 | 2004 | 46 | 0.300 |
Why?
| | Gene Silencing | 2 | 2016 | 246 | 0.300 |
Why?
| | Annexin A2 | 1 | 2003 | 5 | 0.300 |
Why?
| | Annexin A1 | 1 | 2003 | 3 | 0.300 |
Why?
| | Fetal Blood | 1 | 2004 | 62 | 0.300 |
Why?
| | Profilins | 2 | 2014 | 16 | 0.300 |
Why?
| | Rats | 8 | 2013 | 1762 | 0.300 |
Why?
| | Ciliary Neurotrophic Factor | 1 | 2003 | 1 | 0.300 |
Why?
| | Pedigree | 8 | 2016 | 159 | 0.290 |
Why?
| | Cell Culture Techniques | 1 | 2004 | 121 | 0.290 |
Why?
| | Blotting, Western | 4 | 2012 | 538 | 0.280 |
Why?
| | Transfection | 4 | 2012 | 638 | 0.280 |
Why?
| | Wound Healing | 1 | 2003 | 121 | 0.280 |
Why?
| | Vital Capacity | 3 | 2013 | 21 | 0.270 |
Why?
| | Mice, Inbred C57BL | 8 | 2016 | 2285 | 0.270 |
Why?
| | Aquaporins | 1 | 2002 | 5 | 0.270 |
Why?
| | Pulmonary Circulation | 1 | 2002 | 25 | 0.260 |
Why?
| | Capillary Permeability | 1 | 2002 | 24 | 0.260 |
Why?
| | Aged, 80 and over | 8 | 2012 | 2879 | 0.260 |
Why?
| | Anti-Bacterial Agents | 1 | 2005 | 383 | 0.250 |
Why?
| | Genetic Vectors | 2 | 2016 | 484 | 0.250 |
Why?
| | RNA, Small Interfering | 2 | 2014 | 583 | 0.250 |
Why?
| | Neuroglia | 2 | 2015 | 78 | 0.250 |
Why?
| | Lung Volume Measurements | 2 | 2015 | 12 | 0.250 |
Why?
| | Dystrophin | 3 | 2006 | 15 | 0.250 |
Why?
| | Protein Structure, Tertiary | 6 | 2013 | 688 | 0.240 |
Why?
| | Transduction, Genetic | 2 | 2013 | 151 | 0.240 |
Why?
| | Binding Sites | 4 | 2009 | 751 | 0.230 |
Why?
| | Chromosomes, Human, Pair 9 | 2 | 2010 | 12 | 0.230 |
Why?
| | DNA Copy Number Variations | 2 | 2010 | 30 | 0.230 |
Why?
| | Cysteine | 2 | 2013 | 88 | 0.230 |
Why?
| | Molecular Sequence Data | 6 | 2015 | 2055 | 0.230 |
Why?
| | Models, Biological | 5 | 2010 | 982 | 0.230 |
Why?
| | PC12 Cells | 2 | 2012 | 35 | 0.230 |
Why?
| | Genetic Testing | 3 | 2013 | 76 | 0.230 |
Why?
| | Sequence Homology, Amino Acid | 3 | 2016 | 343 | 0.220 |
Why?
| | Sphingolipids | 3 | 2011 | 8 | 0.220 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 698 | 0.220 |
Why?
| | Structure-Activity Relationship | 2 | 2012 | 263 | 0.220 |
Why?
| | Cell Line | 7 | 2012 | 1758 | 0.210 |
Why?
| | Point Mutation | 4 | 2011 | 148 | 0.210 |
Why?
| | Alleles | 3 | 2014 | 308 | 0.210 |
Why?
| | Recombinant Fusion Proteins | 3 | 2011 | 477 | 0.200 |
Why?
| | Drosophila Proteins | 2 | 2015 | 621 | 0.200 |
Why?
| | Action Potentials | 2 | 2013 | 85 | 0.200 |
Why?
| | Ubiquitination | 2 | 2015 | 63 | 0.200 |
Why?
| | Microsatellite Repeats | 2 | 2009 | 34 | 0.200 |
Why?
| | Base Sequence | 4 | 2012 | 1245 | 0.200 |
Why?
| | Protein Binding | 5 | 2017 | 1228 | 0.190 |
Why?
| | Inflammation | 2 | 2015 | 666 | 0.190 |
Why?
| | Chromosome Mapping | 4 | 2016 | 251 | 0.190 |
Why?
| | Organ Size | 1 | 2017 | 128 | 0.190 |
Why?
| | Recombinant Proteins | 4 | 2009 | 614 | 0.190 |
Why?
| | Hela Cells | 2 | 2012 | 484 | 0.190 |
Why?
| | Adolescent | 5 | 2015 | 4030 | 0.190 |
Why?
| | DNA Primers | 4 | 2012 | 302 | 0.190 |
Why?
| | Neural Conduction | 2 | 2015 | 17 | 0.190 |
Why?
| | Environmental Exposure | 2 | 2010 | 123 | 0.180 |
Why?
| | Nervous System Diseases | 2 | 2008 | 57 | 0.180 |
Why?
| | Protein Processing, Post-Translational | 2 | 2015 | 175 | 0.180 |
Why?
| | Age Factors | 3 | 2015 | 1102 | 0.180 |
Why?
| | Polymerase Chain Reaction | 3 | 2012 | 452 | 0.180 |
Why?
| | Respiratory Mechanics | 3 | 2008 | 42 | 0.180 |
Why?
| | Survival Analysis | 1 | 2017 | 386 | 0.180 |
Why?
| | Caveolin 3 | 2 | 2007 | 5 | 0.180 |
Why?
| | Cell Count | 3 | 2006 | 120 | 0.180 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2016 | 7 | 0.180 |
Why?
| | Protein Folding | 2 | 2010 | 256 | 0.170 |
Why?
| | Cyclins | 1 | 2016 | 40 | 0.170 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2015 | 17 | 0.170 |
Why?
| | Mice, Knockout | 3 | 2016 | 1607 | 0.170 |
Why?
| | Corpus Callosum | 1 | 2016 | 33 | 0.170 |
Why?
| | Survival Rate | 3 | 2010 | 494 | 0.170 |
Why?
| | Spirometry | 2 | 2013 | 40 | 0.170 |
Why?
| | Oxidative Stress | 2 | 2015 | 210 | 0.170 |
Why?
| | Oxycodone | 1 | 2015 | 15 | 0.170 |
Why?
| | Tomography, Spiral Computed | 1 | 2015 | 19 | 0.170 |
Why?
| | Apoptosis | 5 | 2012 | 869 | 0.170 |
Why?
| | Protein Transport | 4 | 2017 | 343 | 0.170 |
Why?
| | Calcium | 3 | 2013 | 503 | 0.160 |
Why?
| | Neuromuscular Diseases | 1 | 2015 | 13 | 0.160 |
Why?
| | G-Quadruplexes | 1 | 2014 | 3 | 0.160 |
Why?
| | Copper | 2 | 2007 | 27 | 0.160 |
Why?
| | Cerebral Cortex | 1 | 2015 | 180 | 0.160 |
Why?
| | Cytoskeleton | 1 | 2015 | 121 | 0.160 |
Why?
| | Low Back Pain | 1 | 2015 | 95 | 0.160 |
Why?
| | Tubulin | 1 | 2014 | 73 | 0.150 |
Why?
| | RNA, Messenger | 5 | 2011 | 1255 | 0.150 |
Why?
| | Nervous System | 2 | 2016 | 65 | 0.150 |
Why?
| | Reproducibility of Results | 1 | 2017 | 980 | 0.150 |
Why?
| | Serine | 2 | 2011 | 61 | 0.150 |
Why?
| | Neuregulins | 1 | 2013 | 1 | 0.150 |
Why?
| | HIV Seropositivity | 1 | 2014 | 73 | 0.150 |
Why?
| | Quantitative Trait Loci | 2 | 2012 | 43 | 0.150 |
Why?
| | Central Nervous System | 3 | 2014 | 87 | 0.150 |
Why?
| | Oxidation-Reduction | 2 | 2013 | 228 | 0.150 |
Why?
| | Early Detection of Cancer | 1 | 2014 | 78 | 0.150 |
Why?
| | Models, Molecular | 4 | 2012 | 883 | 0.150 |
Why?
| | Analgesics, Opioid | 1 | 2015 | 168 | 0.150 |
Why?
| | Lung Diseases, Obstructive | 1 | 2013 | 15 | 0.150 |
Why?
| | Mass Spectrometry | 2 | 2013 | 207 | 0.140 |
Why?
| | Respiratory Tract Diseases | 1 | 2013 | 29 | 0.140 |
Why?
| | Exhalation | 1 | 2013 | 15 | 0.140 |
Why?
| | Synaptosomal-Associated Protein 25 | 1 | 2013 | 5 | 0.140 |
Why?
| | Skin | 1 | 2015 | 229 | 0.140 |
Why?
| | Syntaxin 1 | 1 | 2013 | 3 | 0.140 |
Why?
| | Severity of Illness Index | 2 | 2015 | 894 | 0.140 |
Why?
| | Botulinum Toxins | 1 | 2013 | 7 | 0.140 |
Why?
| | Receptor, Epidermal Growth Factor | 1 | 2013 | 82 | 0.140 |
Why?
| | Green Fluorescent Proteins | 3 | 2013 | 296 | 0.140 |
Why?
| | Amino Acid Substitution | 4 | 2013 | 208 | 0.140 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 103 | 0.140 |
Why?
| | Ribonucleases | 1 | 2012 | 27 | 0.140 |
Why?
| | Carbon Dioxide | 1 | 2013 | 63 | 0.140 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2012 | 20 | 0.140 |
Why?
| | Astrocytes | 1 | 2013 | 65 | 0.140 |
Why?
| | Muscle Weakness | 2 | 2010 | 19 | 0.140 |
Why?
| | RNA | 2 | 2016 | 284 | 0.140 |
Why?
| | Multiple Sclerosis | 1 | 2013 | 100 | 0.140 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2004 | 248 | 0.130 |
Why?
| | Neurogenesis | 1 | 2012 | 34 | 0.130 |
Why?
| | Pilot Projects | 2 | 2011 | 497 | 0.130 |
Why?
| | Gene Expression Profiling | 2 | 2012 | 480 | 0.130 |
Why?
| | RNA-Binding Proteins | 1 | 2015 | 294 | 0.130 |
Why?
| | Immunoprecipitation | 1 | 2012 | 120 | 0.130 |
Why?
| | Charcot-Marie-Tooth Disease | 2 | 2015 | 5 | 0.130 |
Why?
| | Sphingosine | 1 | 2011 | 16 | 0.130 |
Why?
| | Neovascularization, Physiologic | 1 | 2012 | 94 | 0.130 |
Why?
| | Cell Membrane | 3 | 2013 | 419 | 0.130 |
Why?
| | T-Lymphocytes | 2 | 2008 | 899 | 0.130 |
Why?
| | Exocytosis | 2 | 2013 | 67 | 0.130 |
Why?
| | Distal Myopathies | 1 | 2011 | 2 | 0.130 |
Why?
| | Risk Factors | 5 | 2014 | 3037 | 0.130 |
Why?
| | Treatment Outcome | 2 | 2015 | 2681 | 0.130 |
Why?
| | Contractile Proteins | 1 | 2011 | 9 | 0.130 |
Why?
| | Family Health | 2 | 2016 | 67 | 0.130 |
Why?
| | tau Proteins | 2 | 2009 | 31 | 0.130 |
Why?
| | Drosophila melanogaster | 1 | 2015 | 395 | 0.120 |
Why?
| | Autoantibodies | 1 | 2011 | 117 | 0.120 |
Why?
| | Macrophages, Alveolar | 1 | 2011 | 34 | 0.120 |
Why?
| | Lung Neoplasms | 1 | 2014 | 295 | 0.120 |
Why?
| | Infusions, Intravenous | 2 | 2008 | 143 | 0.120 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2010 | 42 | 0.120 |
Why?
| | Epitope Mapping | 1 | 2010 | 35 | 0.120 |
Why?
| | Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2010 | 10 | 0.120 |
Why?
| | Bronchiolitis Obliterans | 1 | 2010 | 8 | 0.120 |
Why?
| | Lung Transplantation | 1 | 2010 | 18 | 0.120 |
Why?
| | Basophils | 1 | 2010 | 12 | 0.120 |
Why?
| | Inclusion Bodies | 1 | 2010 | 14 | 0.120 |
Why?
| | Liver | 2 | 2004 | 542 | 0.120 |
Why?
| | Esterases | 1 | 2010 | 7 | 0.120 |
Why?
| | Population | 1 | 2010 | 12 | 0.120 |
Why?
| | Hypersensitivity, Immediate | 1 | 2010 | 10 | 0.120 |
Why?
| | Chromosomes, Human, Pair 16 | 2 | 2016 | 17 | 0.120 |
Why?
| | Protein Biosynthesis | 2 | 2010 | 265 | 0.120 |
Why?
| | Microfilament Proteins | 1 | 2011 | 83 | 0.120 |
Why?
| | Potassium Channels | 1 | 2010 | 49 | 0.120 |
Why?
| | Kyphosis | 1 | 2010 | 8 | 0.120 |
Why?
| | Hypokalemic Periodic Paralysis | 1 | 2010 | 1 | 0.120 |
Why?
| | RNA Interference | 2 | 2013 | 508 | 0.120 |
Why?
| | Lameness, Animal | 1 | 2010 | 7 | 0.120 |
Why?
| | Diagnosis, Differential | 3 | 2006 | 639 | 0.120 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2010 | 7 | 0.120 |
Why?
| | Muscle Denervation | 1 | 2009 | 3 | 0.120 |
Why?
| | Analysis of Variance | 3 | 2006 | 534 | 0.120 |
Why?
| | Electric Stimulation | 2 | 2008 | 108 | 0.120 |
Why?
| | Gene Dosage | 1 | 2010 | 45 | 0.120 |
Why?
| | Myostatin | 1 | 2009 | 8 | 0.110 |
Why?
| | Muscle Cells | 1 | 2009 | 15 | 0.110 |
Why?
| | DNA Helicases | 1 | 2011 | 137 | 0.110 |
Why?
| | Calcium-Binding Proteins | 1 | 2010 | 52 | 0.110 |
Why?
| | Animals, Newborn | 4 | 2016 | 233 | 0.110 |
Why?
| | Genetic Loci | 1 | 2009 | 51 | 0.110 |
Why?
| | Crystallography, X-Ray | 1 | 2010 | 288 | 0.110 |
Why?
| | Histone Deacetylases | 1 | 2009 | 50 | 0.110 |
Why?
| | Sequence Analysis, RNA | 1 | 2009 | 67 | 0.110 |
Why?
| | Molecular Chaperones | 1 | 2010 | 77 | 0.110 |
Why?
| | Genes, Recessive | 1 | 2009 | 40 | 0.110 |
Why?
| | Graft Rejection | 1 | 2010 | 192 | 0.110 |
Why?
| | Neurodegenerative Diseases | 1 | 2009 | 39 | 0.110 |
Why?
| | Endoplasmic Reticulum | 1 | 2010 | 128 | 0.110 |
Why?
| | Animals, Genetically Modified | 3 | 2016 | 218 | 0.110 |
Why?
| | Risk | 1 | 2010 | 345 | 0.110 |
Why?
| | Signal Transduction | 4 | 2013 | 2303 | 0.110 |
Why?
| | Plethysmography, Whole Body | 2 | 2005 | 4 | 0.110 |
Why?
| | Trans-Activators | 1 | 2011 | 282 | 0.110 |
Why?
| | Cytoprotection | 1 | 2008 | 13 | 0.110 |
Why?
| | Superior Colliculi | 1 | 2008 | 12 | 0.110 |
Why?
| | Conserved Sequence | 1 | 2009 | 167 | 0.110 |
Why?
| | Quebec | 1 | 2008 | 5 | 0.110 |
Why?
| | Stress, Physiological | 1 | 2010 | 121 | 0.100 |
Why?
| | Scotland | 1 | 2008 | 10 | 0.100 |
Why?
| | Ireland | 1 | 2008 | 13 | 0.100 |
Why?
| | Hydroxylamines | 1 | 2008 | 6 | 0.100 |
Why?
| | Brain Stem | 1 | 2008 | 29 | 0.100 |
Why?
| | Sp1 Transcription Factor | 1 | 2008 | 21 | 0.100 |
Why?
| | United States | 4 | 2012 | 4028 | 0.100 |
Why?
| | Histone Acetyltransferases | 1 | 2008 | 61 | 0.100 |
Why?
| | Interleukin-4 | 2 | 2008 | 204 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 530 | 0.100 |
Why?
| | Smoking | 1 | 2014 | 756 | 0.100 |
Why?
| | Homozygote | 1 | 2008 | 103 | 0.100 |
Why?
| | Multigene Family | 1 | 2008 | 94 | 0.100 |
Why?
| | RNA Splice Sites | 1 | 2008 | 28 | 0.100 |
Why?
| | Convulsants | 1 | 2008 | 2 | 0.100 |
Why?
| | Benzodiazepinones | 1 | 2008 | 2 | 0.100 |
Why?
| | Isoenzymes | 1 | 2008 | 131 | 0.100 |
Why?
| | Receptors, GABA | 1 | 2008 | 4 | 0.100 |
Why?
| | Glutamic Acid | 2 | 2006 | 66 | 0.100 |
Why?
| | Nerve Net | 1 | 2008 | 57 | 0.100 |
Why?
| | Birth Order | 1 | 2007 | 3 | 0.100 |
Why?
| | Autophagy | 1 | 2009 | 122 | 0.100 |
Why?
| | Nerve Regeneration | 1 | 2008 | 22 | 0.100 |
Why?
| | Caspases | 2 | 2006 | 135 | 0.100 |
Why?
| | Occupational Exposure | 1 | 2010 | 219 | 0.100 |
Why?
| | CHO Cells | 2 | 2005 | 190 | 0.100 |
Why?
| | Supranuclear Palsy, Progressive | 1 | 2007 | 1 | 0.100 |
Why?
| | Cell Line, Tumor | 2 | 2016 | 862 | 0.100 |
Why?
| | Protein Isoforms | 2 | 2007 | 168 | 0.100 |
Why?
| | Exons | 1 | 2008 | 156 | 0.100 |
Why?
| | Prognosis | 2 | 2010 | 944 | 0.100 |
Why?
| | Actinin | 1 | 2007 | 6 | 0.100 |
Why?
| | Tumor Cells, Cultured | 2 | 2009 | 385 | 0.100 |
Why?
| | HIV Infections | 1 | 2013 | 664 | 0.100 |
Why?
| | Embryonic Stem Cells | 1 | 2008 | 112 | 0.100 |
Why?
| | Cricetinae | 2 | 2005 | 405 | 0.100 |
Why?
| | Drug Delivery Systems | 1 | 2009 | 165 | 0.090 |
Why?
| | Data Interpretation, Statistical | 1 | 2008 | 168 | 0.090 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2011 | 380 | 0.090 |
Why?
| | Dystrophin-Associated Protein Complex | 1 | 2006 | 1 | 0.090 |
Why?
| | Xenon | 1 | 2007 | 7 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2011 | 694 | 0.090 |
Why?
| | Microtubule-Associated Proteins | 2 | 2009 | 119 | 0.090 |
Why?
| | Sciatic Nerve | 3 | 2012 | 17 | 0.090 |
Why?
| | Creatine Kinase | 1 | 2006 | 41 | 0.090 |
Why?
| | Regression Analysis | 1 | 2008 | 425 | 0.090 |
Why?
| | Early Diagnosis | 1 | 2006 | 44 | 0.090 |
Why?
| | Gait Ataxia | 1 | 2006 | 1 | 0.090 |
Why?
| | Myelin P0 Protein | 1 | 2006 | 1 | 0.090 |
Why?
| | Saccharomyces cerevisiae | 1 | 2011 | 432 | 0.090 |
Why?
| | Lod Score | 2 | 2003 | 28 | 0.090 |
Why?
| | Glutamate Plasma Membrane Transport Proteins | 1 | 2006 | 1 | 0.090 |
Why?
| | Blotting, Northern | 2 | 2008 | 158 | 0.090 |
Why?
| | Residual Volume | 1 | 2006 | 2 | 0.090 |
Why?
| | Respiratory Muscles | 1 | 2006 | 7 | 0.090 |
Why?
| | Albuterol | 1 | 2006 | 12 | 0.090 |
Why?
| | Adrenergic beta-Agonists | 1 | 2006 | 21 | 0.090 |
Why?
| | Electromyography | 3 | 2016 | 72 | 0.090 |
Why?
| | Hypercapnia | 1 | 2005 | 7 | 0.090 |
Why?
| | Dementia | 1 | 2007 | 121 | 0.090 |
Why?
| | Methyl Ethers | 1 | 2005 | 8 | 0.090 |
Why?
| | Isoflurane | 1 | 2005 | 15 | 0.090 |
Why?
| | Pancreas, Exocrine | 1 | 2005 | 7 | 0.090 |
Why?
| | Zebrafish | 3 | 2016 | 221 | 0.090 |
Why?
| | Product Labeling | 1 | 2005 | 6 | 0.090 |
Why?
| | Drug Packaging | 1 | 2005 | 14 | 0.090 |
Why?
| | Pharmacy Service, Hospital | 1 | 2005 | 16 | 0.080 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2008 | 426 | 0.080 |
Why?
| | Cricetulus | 1 | 2005 | 77 | 0.080 |
Why?
| | Phenylbutyrates | 1 | 2005 | 3 | 0.080 |
Why?
| | Mice, Inbred C3H | 1 | 2005 | 173 | 0.080 |
Why?
| | Glycoproteins | 1 | 2006 | 158 | 0.080 |
Why?
| | Drug Labeling | 1 | 2005 | 29 | 0.080 |
Why?
| | Dyneins | 1 | 2006 | 78 | 0.080 |
Why?
| | Axotomy | 3 | 2012 | 14 | 0.080 |
Why?
| | Species Specificity | 1 | 2005 | 298 | 0.080 |
Why?
| | Biological Transport | 3 | 2016 | 240 | 0.080 |
Why?
| | Endosomes | 1 | 2005 | 138 | 0.080 |
Why?
| | Europe | 3 | 2012 | 116 | 0.080 |
Why?
| | Hyperoxia | 1 | 2004 | 11 | 0.080 |
Why?
| | Powders | 1 | 2004 | 9 | 0.080 |
Why?
| | Calpain | 1 | 2004 | 7 | 0.080 |
Why?
| | Caveolins | 1 | 2004 | 7 | 0.080 |
Why?
| | Creatine | 1 | 2004 | 13 | 0.080 |
Why?
| | Cohort Studies | 3 | 2014 | 1417 | 0.080 |
Why?
| | Protein Structure, Secondary | 2 | 2003 | 222 | 0.080 |
Why?
| | Behavior, Animal | 1 | 2005 | 137 | 0.080 |
Why?
| | Cloning, Molecular | 2 | 2003 | 360 | 0.080 |
Why?
| | Chi-Square Distribution | 1 | 2005 | 366 | 0.080 |
Why?
| | Leptin | 1 | 2004 | 54 | 0.080 |
Why?
| | Cell Aggregation | 1 | 2004 | 21 | 0.080 |
Why?
| | Infant, Newborn | 1 | 2006 | 730 | 0.080 |
Why?
| | Molecular Weight | 1 | 2004 | 170 | 0.080 |
Why?
| | Apolipoproteins E | 1 | 2004 | 63 | 0.080 |
Why?
| | Disulfides | 1 | 2004 | 47 | 0.080 |
Why?
| | Isoxazoles | 1 | 2004 | 5 | 0.080 |
Why?
| | Antigens, CD8 | 1 | 2004 | 54 | 0.080 |
Why?
| | Gene Targeting | 1 | 2004 | 74 | 0.080 |
Why?
| | Infarction, Middle Cerebral Artery | 1 | 2004 | 42 | 0.080 |
Why?
| | Antigens, CD34 | 1 | 2004 | 46 | 0.080 |
Why?
| | Macromolecular Substances | 1 | 2004 | 141 | 0.080 |
Why?
| | Tacrolimus | 1 | 2004 | 23 | 0.080 |
Why?
| | Cell Transplantation | 1 | 2004 | 36 | 0.080 |
Why?
| | Genome, Human | 3 | 2010 | 141 | 0.070 |
Why?
| | Respiratory Physiological Phenomena | 1 | 2003 | 7 | 0.070 |
Why?
| | Mice, Mutant Strains | 1 | 2004 | 283 | 0.070 |
Why?
| | Chromosomes, Human, Pair 20 | 1 | 2003 | 8 | 0.070 |
Why?
| | Precipitin Tests | 1 | 2003 | 95 | 0.070 |
Why?
| | DNA, Complementary | 1 | 2004 | 181 | 0.070 |
Why?
| | Neurites | 2 | 2016 | 20 | 0.070 |
Why?
| | Meta-Analysis as Topic | 2 | 2014 | 61 | 0.070 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 161 | 0.070 |
Why?
| | Antigens, CD4 | 1 | 2004 | 123 | 0.070 |
Why?
| | Chromosomes, Human, Pair 2 | 1 | 2003 | 8 | 0.070 |
Why?
| | Particle Size | 1 | 2004 | 245 | 0.070 |
Why?
| | Cell Aging | 1 | 2004 | 77 | 0.070 |
Why?
| | Stress, Mechanical | 1 | 2003 | 109 | 0.070 |
Why?
| | Acyltransferases | 1 | 2002 | 18 | 0.070 |
Why?
| | Adaptation, Physiological | 1 | 2003 | 75 | 0.070 |
Why?
| | Cell Lineage | 1 | 2004 | 204 | 0.070 |
Why?
| | European Continental Ancestry Group | 3 | 2012 | 424 | 0.070 |
Why?
| | Caenorhabditis elegans | 1 | 2007 | 380 | 0.070 |
Why?
| | Leukocytes, Mononuclear | 1 | 2004 | 215 | 0.070 |
Why?
| | Spleen | 1 | 2004 | 455 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2004 | 204 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2003 | 270 | 0.070 |
Why?
| | Aquaporin 1 | 1 | 2002 | 2 | 0.070 |
Why?
| | Blood Group Antigens | 1 | 2002 | 5 | 0.070 |
Why?
| | Insects | 1 | 2002 | 25 | 0.070 |
Why?
| | Microscopy, Immunoelectron | 1 | 2002 | 27 | 0.070 |
Why?
| | Kidney | 1 | 2004 | 280 | 0.070 |
Why?
| | Injections, Intraventricular | 2 | 2016 | 15 | 0.070 |
Why?
| | Stem Cells | 1 | 2004 | 202 | 0.070 |
Why?
| | Chromosomes, Human, Pair 18 | 1 | 2001 | 3 | 0.070 |
Why?
| | Transcription Factors | 1 | 2009 | 1204 | 0.070 |
Why?
| | Microscopy, Fluorescence | 1 | 2003 | 363 | 0.070 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2002 | 21 | 0.070 |
Why?
| | Brain Ischemia | 1 | 2004 | 198 | 0.070 |
Why?
| | Protein Engineering | 1 | 2002 | 53 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2015 | 488 | 0.060 |
Why?
| | Phosphorylation | 2 | 2013 | 673 | 0.060 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2002 | 74 | 0.060 |
Why?
| | Drosophila | 3 | 2012 | 380 | 0.060 |
Why?
| | Cercopithecus aethiops | 2 | 2014 | 175 | 0.060 |
Why?
| | Actins | 2 | 2012 | 214 | 0.060 |
Why?
| | Retrospective Studies | 3 | 2015 | 2568 | 0.060 |
Why?
| | Monocytes | 1 | 2002 | 299 | 0.060 |
Why?
| | Cytoplasm | 2 | 2011 | 231 | 0.060 |
Why?
| | Protein-Serine-Threonine Kinases | 2 | 2015 | 322 | 0.060 |
Why?
| | Algorithms | 1 | 2003 | 634 | 0.060 |
Why?
| | Prospective Studies | 2 | 2014 | 1671 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 2 | 2013 | 475 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2002 | 685 | 0.050 |
Why?
| | Oxygen | 2 | 2013 | 208 | 0.050 |
Why?
| | Administration, Oral | 2 | 2011 | 202 | 0.050 |
Why?
| | Up-Regulation | 2 | 2009 | 325 | 0.050 |
Why?
| | Organelles | 1 | 2016 | 14 | 0.050 |
Why?
| | Prions | 1 | 2016 | 24 | 0.050 |
Why?
| | Child | 1 | 2003 | 2652 | 0.050 |
Why?
| | Lateral Ventricles | 1 | 2016 | 5 | 0.040 |
Why?
| | Enzyme Stability | 2 | 2007 | 41 | 0.040 |
Why?
| | Delayed-Action Preparations | 1 | 2015 | 55 | 0.040 |
Why?
| | Embryo, Nonmammalian | 1 | 2016 | 149 | 0.040 |
Why?
| | Intellectual Property | 1 | 2015 | 3 | 0.040 |
Why?
| | Transcription Factor TFIIIA | 1 | 2015 | 4 | 0.040 |
Why?
| | Turkey | 1 | 2015 | 11 | 0.040 |
Why?
| | TRPM Cation Channels | 1 | 2015 | 6 | 0.040 |
Why?
| | Larva | 1 | 2015 | 138 | 0.040 |
Why?
| | Genetic Markers | 2 | 2007 | 106 | 0.040 |
Why?
| | Caspase 3 | 2 | 2006 | 76 | 0.040 |
Why?
| | Government Regulation | 1 | 2015 | 35 | 0.040 |
Why?
| | Ubiquitins | 1 | 2015 | 38 | 0.040 |
Why?
| | Pain Measurement | 1 | 2015 | 192 | 0.040 |
Why?
| | Oncogene Proteins | 1 | 2015 | 42 | 0.040 |
Why?
| | CD4 Lymphocyte Count | 1 | 2014 | 86 | 0.040 |
Why?
| | Dimerization | 2 | 2005 | 154 | 0.040 |
Why?
| | Pulmonary Emphysema | 1 | 2014 | 27 | 0.040 |
Why?
| | Models, Genetic | 2 | 2007 | 225 | 0.040 |
Why?
| | Injections, Spinal | 1 | 2013 | 17 | 0.040 |
Why?
| | Callithrix | 1 | 2013 | 9 | 0.040 |
Why?
| | Cerebrospinal Fluid | 1 | 2013 | 8 | 0.040 |
Why?
| | Canada | 1 | 2013 | 68 | 0.040 |
Why?
| | Asian Continental Ancestry Group | 1 | 2013 | 40 | 0.040 |
Why?
| | Decapodiformes | 1 | 2013 | 9 | 0.040 |
Why?
| | Hydrogen Peroxide | 1 | 2013 | 73 | 0.040 |
Why?
| | Culture Media, Conditioned | 1 | 2013 | 44 | 0.040 |
Why?
| | Data Collection | 1 | 2015 | 369 | 0.040 |
Why?
| | Kinesin | 1 | 2013 | 47 | 0.040 |
Why?
| | Sodium | 1 | 2013 | 53 | 0.040 |
Why?
| | Respiratory Function Tests | 1 | 2013 | 96 | 0.040 |
Why?
| | Transgenes | 1 | 2013 | 111 | 0.040 |
Why?
| | Synaptic Vesicles | 1 | 2013 | 22 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2015 | 223 | 0.040 |
Why?
| | Jews | 1 | 2012 | 16 | 0.030 |
Why?
| | Growth Cones | 1 | 2012 | 17 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 309 | 0.030 |
Why?
| | Viral Load | 1 | 2013 | 171 | 0.030 |
Why?
| | Denervation | 1 | 2012 | 10 | 0.030 |
Why?
| | Superior Cervical Ganglion | 1 | 2012 | 16 | 0.030 |
Why?
| | Xanthomatosis, Cerebrotendinous | 1 | 2012 | 2 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2016 | 488 | 0.030 |
Why?
| | Tissue Culture Techniques | 1 | 2012 | 18 | 0.030 |
Why?
| | In Situ Hybridization | 1 | 2012 | 201 | 0.030 |
Why?
| | Depression, Chemical | 1 | 2011 | 18 | 0.030 |
Why?
| | Survival | 1 | 2011 | 10 | 0.030 |
Why?
| | Stereoisomerism | 1 | 2011 | 44 | 0.030 |
Why?
| | Endocytosis | 1 | 2013 | 135 | 0.030 |
Why?
| | Alanine | 1 | 2011 | 38 | 0.030 |
Why?
| | Incidence | 1 | 2014 | 816 | 0.030 |
Why?
| | Infertility, Male | 1 | 2011 | 32 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2013 | 140 | 0.030 |
Why?
| | Prevalence | 1 | 2014 | 795 | 0.030 |
Why?
| | Chromosomes, Human, Pair 7 | 1 | 2011 | 9 | 0.030 |
Why?
| | Italy | 1 | 2011 | 40 | 0.030 |
Why?
| | Thiocyanates | 1 | 2011 | 15 | 0.030 |
Why?
| | Australia | 1 | 2011 | 47 | 0.030 |
Why?
| | Haemophilus influenzae | 1 | 2011 | 29 | 0.030 |
Why?
| | Recombination, Genetic | 2 | 2003 | 211 | 0.030 |
Why?
| | Comorbidity | 1 | 2013 | 733 | 0.030 |
Why?
| | Spastic Paraplegia, Hereditary | 1 | 2010 | 2 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 2011 | 124 | 0.030 |
Why?
| | Pseudomonas aeruginosa | 1 | 2011 | 60 | 0.030 |
Why?
| | Internationality | 1 | 2010 | 29 | 0.030 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2010 | 19 | 0.030 |
Why?
| | Neurofilament Proteins | 1 | 2010 | 10 | 0.030 |
Why?
| | Mice, Neurologic Mutants | 1 | 2010 | 15 | 0.030 |
Why?
| | Postoperative Period | 1 | 2010 | 87 | 0.030 |
Why?
| | Receptors, Immunologic | 1 | 2011 | 155 | 0.030 |
Why?
| | Fumonisins | 1 | 2010 | 2 | 0.030 |
Why?
| | Phagocytosis | 1 | 2011 | 193 | 0.030 |
Why?
| | Electrophysiological Phenomena | 1 | 2010 | 8 | 0.030 |
Why?
| | Chick Embryo | 1 | 2010 | 56 | 0.030 |
Why?
| | Triiodothyronine | 1 | 2010 | 25 | 0.030 |
Why?
| | RNA Editing | 1 | 2010 | 24 | 0.030 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2009 | 14 | 0.030 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2010 | 111 | 0.030 |
Why?
| | Protein Conformation | 1 | 2012 | 601 | 0.030 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2009 | 13 | 0.030 |
Why?
| | Injections, Intramuscular | 1 | 2009 | 49 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2015 | 698 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 2009 | 99 | 0.030 |
Why?
| | Spodoptera | 1 | 2009 | 27 | 0.030 |
Why?
| | Biological Availability | 1 | 2009 | 93 | 0.030 |
Why?
| | Endoribonucleases | 1 | 2009 | 45 | 0.030 |
Why?
| | Longevity | 1 | 2009 | 58 | 0.030 |
Why?
| | Family | 1 | 2010 | 155 | 0.030 |
Why?
| | Substrate Specificity | 1 | 2010 | 257 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2009 | 203 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2009 | 139 | 0.030 |
Why?
| | Antigens, CD11c | 1 | 2008 | 6 | 0.030 |
Why?
| | Lymphocytes | 1 | 2010 | 181 | 0.030 |
Why?
| | Antigens, CD | 1 | 2010 | 293 | 0.030 |
Why?
| | Oscillometry | 1 | 2008 | 15 | 0.030 |
Why?
| | Excitatory Amino Acid Agonists | 1 | 2008 | 15 | 0.030 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2008 | 54 | 0.030 |
Why?
| | RNA Splicing | 1 | 2010 | 139 | 0.030 |
Why?
| | Neural Pathways | 1 | 2008 | 60 | 0.030 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2008 | 48 | 0.030 |
Why?
| | Cell Separation | 1 | 2008 | 133 | 0.030 |
Why?
| | Patch-Clamp Techniques | 1 | 2008 | 132 | 0.030 |
Why?
| | Blood-Brain Barrier | 1 | 2008 | 40 | 0.030 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2008 | 85 | 0.030 |
Why?
| | Vibrissae | 1 | 2008 | 4 | 0.030 |
Why?
| | Membrane Potentials | 1 | 2008 | 150 | 0.030 |
Why?
| | Facial Nerve | 1 | 2008 | 9 | 0.030 |
Why?
| | Isoquinolines | 1 | 2008 | 19 | 0.030 |
Why?
| | Functional Laterality | 1 | 2008 | 115 | 0.030 |
Why?
| | Ganglia, Spinal | 1 | 2008 | 18 | 0.030 |
Why?
| | Synapses | 1 | 2009 | 132 | 0.030 |
Why?
| | Siblings | 1 | 2007 | 24 | 0.020 |
Why?
| | Neurons, Afferent | 1 | 2008 | 24 | 0.020 |
Why?
| | Inheritance Patterns | 1 | 2007 | 13 | 0.020 |
Why?
| | Lipids | 1 | 2010 | 230 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2011 | 496 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2007 | 87 | 0.020 |
Why?
| | Microglia | 1 | 2008 | 81 | 0.020 |
Why?
| | Trinucleotide Repeats | 1 | 2007 | 13 | 0.020 |
Why?
| | Databases, Genetic | 1 | 2007 | 48 | 0.020 |
Why?
| | Founder Effect | 1 | 2007 | 9 | 0.020 |
Why?
| | Chromatography, Affinity | 1 | 2007 | 43 | 0.020 |
Why?
| | Mesencephalon | 1 | 2006 | 19 | 0.020 |
Why?
| | Alternative Splicing | 1 | 2007 | 101 | 0.020 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2006 | 31 | 0.020 |
Why?
| | Spinal Nerve Roots | 1 | 2006 | 7 | 0.020 |
Why?
| | Dysarthria | 1 | 2006 | 7 | 0.020 |
Why?
| | Paresis | 1 | 2006 | 3 | 0.020 |
Why?
| | Polyneuropathies | 1 | 2006 | 3 | 0.020 |
Why?
| | Gene Deletion | 1 | 2007 | 235 | 0.020 |
Why?
| | Hypesthesia | 1 | 2006 | 7 | 0.020 |
Why?
| | COS Cells | 1 | 2007 | 194 | 0.020 |
Why?
| | Spinal Diseases | 1 | 2006 | 15 | 0.020 |
Why?
| | Open Reading Frames | 1 | 2006 | 60 | 0.020 |
Why?
| | Cytoplasmic Dyneins | 1 | 2006 | 6 | 0.020 |
Why?
| | Dopamine | 1 | 2006 | 67 | 0.020 |
Why?
| | Expressed Sequence Tags | 1 | 2006 | 18 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2006 | 90 | 0.020 |
Why?
| | Osteoarthritis | 1 | 2006 | 33 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2010 | 1550 | 0.020 |
Why?
| | Leg | 1 | 2006 | 73 | 0.020 |
Why?
| | Purkinje Cells | 1 | 2005 | 5 | 0.020 |
Why?
| | Blotting, Southern | 1 | 2005 | 49 | 0.020 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2005 | 8 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2008 | 383 | 0.020 |
Why?
| | Electrophysiology | 1 | 2005 | 92 | 0.020 |
Why?
| | Epidermal Growth Factor | 1 | 2005 | 52 | 0.020 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2006 | 92 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2005 | 194 | 0.020 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2005 | 24 | 0.020 |
Why?
| | Cytochromes c | 1 | 2005 | 25 | 0.020 |
Why?
| | Curcumin | 1 | 2005 | 14 | 0.020 |
Why?
| | Acetylation | 1 | 2005 | 98 | 0.020 |
Why?
| | Protein Precursors | 1 | 2005 | 67 | 0.020 |
Why?
| | Protein Denaturation | 1 | 2005 | 75 | 0.020 |
Why?
| | Oocytes | 1 | 2006 | 162 | 0.020 |
Why?
| | Injections, Intraperitoneal | 1 | 2004 | 46 | 0.020 |
Why?
| | Mice, Obese | 1 | 2004 | 33 | 0.020 |
Why?
| | Electron Transport Complex IV | 1 | 2004 | 10 | 0.020 |
Why?
| | Premedication | 1 | 2004 | 10 | 0.020 |
Why?
| | Chromatography, Gel | 1 | 2004 | 62 | 0.020 |
Why?
| | Eating | 1 | 2004 | 97 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2004 | 330 | 0.020 |
Why?
| | Centromere | 1 | 2003 | 24 | 0.020 |
Why?
| | NF-kappa B | 1 | 2005 | 386 | 0.020 |
Why?
| | Amino Acid Motifs | 1 | 2003 | 124 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2004 | 229 | 0.020 |
Why?
| | Body Weight | 1 | 2004 | 348 | 0.020 |
Why?
| | Histones | 1 | 2005 | 329 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2004 | 263 | 0.020 |
Why?
| | Protein Subunits | 1 | 2002 | 147 | 0.020 |
Why?
| | Microtubules | 1 | 2003 | 198 | 0.020 |
Why?
|
|
Brown's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|